Pulmatrix Inc. (PULM) announced Tuesday morning that the FDA has designated PUR1900, its drug candidate for treating fungal infections in the lungs of CF patients, as a "Qualified Infectious Disease Product."
from RTT - Before the Bell http://ift.tt/2iHZHHk
via IFTTT
No comments:
Post a Comment